Immune Checkpoint Inhibitors - Latest Research in Cancer Immunotherapy (en Inglés)
Reseña del libro "Immune Checkpoint Inhibitors - Latest Research in Cancer Immunotherapy (en Inglés)"
Cancer remains one of the most complex and challenging diseases today. Advances in genomics, epigenetics, immunology, and systems biology have deepened our understanding of how tumors develop and resist treatment. Breakthroughs in cancer immunotherapy are transforming research and clinical practice. The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy, turning once-deadly diagnoses into manageable conditions for many patients. By activating the body's immune response against tumors, treatments targeting PD-1, PD-L1, CTLA-4, and emerging pathways have ushered in a new era of precision oncology. Immune Checkpoint Inhibitors - Latest Research in Cancer Immunotherapy offers a comprehensive, up-to-date overview of scientific advances, clinical applications, and future prospects of checkpoint blockade therapy. Featuring contributions from researchers and clinicians, this book explores mechanisms of immune regulation, response and resistance biomarkers, combination therapies with antiangiogenic drugs, and the immunoregulatory roles of the gut microbiome and lipids. The book covers fundamental concepts and recent innovations across a wide range of cancers, including melanoma, lung, gynecologic, genitourinary, and gastrointestinal cancers. It emphasizes molecular mechanisms of sensitivity and resistance, combination therapeutic approaches, toxicity, and immune modulation. Essential for oncologists, immunologists, cancer researchers, fellows, graduate students, and healthcare providers, this volume offers valuable insights into one of the fastest-evolving areas of modern medicine. Key Features: ¿ Comprehensive overview of immune checkpoint biology and tumor-immune interactions ¿ Latest advances in predictive biomarkers and mechanisms of therapeutic resistance ¿ Clinical applications across multiple cancer types ¿ Coverage of combination therapies with antiangiogenic drugs ¿ Contributions from internationally recognized experts in oncology and immunology ¿ The immune-regulating effect of lipids and gut microbiota on ICI efficacy The targeted audience is researchers, clinicians, and students at the forefront of cancer immunology and precision oncology.
